Asante now offers Bispecific Antibody Immunotherapy (BsAb) and Bispecific T-Cell Engager (BiTE therapy) — a leading-edge treatment that helps the immune system target and destroy cancer cells.
Until now, patients had to travel hours to begin this treatment, which must take place in an inpatient hospital setting. Making this groundbreaking therapy available in our region — from start to finish — is the result of coordinated efforts across Asante.
This kind of collaborative advance is further fulfillment of the transformative philanthropy that built our cancer centers. The Medical Oncology Unit at Asante Rogue Regional, where BiTE therapy is initiated, is poised for even greater growth, with donor support.
“Oncology is one of the most rapidly changing fields. Bispecifics are an exciting new treatment option available to us. Our goal at Asante is always to provide the latest treatments to our patients locally.”
— Mujahid Rizvi, MD, FACP, MPH, Heimann Medical Chair of Oncology and Medical Director
Planning is currently underway to reimagine what cancer care inside the hospital can be. Right now, the most sensitive treatments and complex cancer care are taking place in the original 1958 wing of the hospital. While the care is exceptional, the facility must be enhanced to better serve people with cancer from across the region.
Philanthropy will drive the transformation to create the best possible experience for patients and families, offering the most precise and efficient care with integrated technology in a peaceful, healing environment.
To become involved in this vital effort, contact Christian Gold Stagg or make a gift directed to Medical Oncology Renovation.